{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"31"}],"units":"Participants"}],"description":"Will be graded by Common Terminology Criteria for Adverse Events version 4.0. Observed DLT rates will be summarized based on the DLT-Evaluable analysis set. Outcome reported as count of participants in each arm who experienced a DLT.","groups":[{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 1 contains patients treated at Dose Level 0 (1 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^4 - 2.80 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"OG000","title":"Dose Level 0 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 2 contains patients treated at Dose Level 1 (3.3 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^5 - 8.50 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"OG001","title":"Dose Level 1 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 3 contains patients treated at Dose Level 2 (1 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^5 - 2.80 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"OG002","title":"Dose Level 2 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 4 contains patients treated at Dose Level 3 (3.3 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^6 - 8.50 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"OG003","title":"Dose Level 3 of CD20 CAR-T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 5 contains patients treated at Dose Level 4 (1 x 10\\^7 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: \\> 8.5 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"OG004","title":"Dose Level 4 of CD20 CAR-T Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Dose-limiting Toxicities (DLT) Rate","type":"PRIMARY","unitOfMeasure":"participants"}